Loading...

Aimmune Therapeutics

DB:5TA
Snowflake Description

Flawless balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
5TA
DB
$1B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. The last earnings update was 49 days ago. More info.


Add to Portfolio Compare Print
  • Aimmune Therapeutics has significant price volatility in the past 3 months.
5TA Share Price and Events
7 Day Returns
-8.7%
DB:5TA
-0.7%
DE Biotechs
2.5%
DE Market
1 Year Returns
-30.9%
DB:5TA
-9.2%
DE Biotechs
-6.7%
DE Market
5TA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Aimmune Therapeutics (5TA) -8.7% -7.6% -10.3% -30.9% 46.3% -
DE Biotechs -0.7% 4.7% -6.2% -9.2% 44% 8.7%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • 5TA underperformed the Biotechs industry which returned -9.2% over the past year.
  • 5TA underperformed the Market in Germany which returned -6.7% over the past year.
Price Volatility
5TA
Industry
5yr Volatility vs Market
Related Companies

5TA Value

 Is Aimmune Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Aimmune Therapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Aimmune Therapeutics.

DB:5TA Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 11 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:5TA
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.46
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.456 (1 + (1- 21%) (0.01%))
1.306
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.31
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.306 * 5.96%)
8.01%

Discounted Cash Flow Calculation for DB:5TA using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Aimmune Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:5TA DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.01%)
2019 -247.00 Analyst x1 -228.68
2020 -196.45 Analyst x2 -168.40
2021 8.28 Analyst x2 6.57
2022 363.21 Analyst x1 266.88
2023 505.57 Analyst x1 343.94
2024 598.14 Est @ 18.31% 376.74
2025 675.22 Est @ 12.89% 393.75
2026 736.58 Est @ 9.09% 397.68
2027 783.94 Est @ 6.43% 391.86
2028 819.77 Est @ 4.57% 379.39
Present value of next 10 years cash flows $2,159.72
DB:5TA DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $819.77 × (1 + 0.23%) ÷ (8.01% – 0.23%)
$10,559.16
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $10,559.16 ÷ (1 + 8.01%)10
$4,886.75
DB:5TA Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $2,159.72 + $4,886.75
$7,046.46
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $7,046.46 / 62.47
$112.8
DB:5TA Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:5TA represents 0.88748x of NasdaqGS:AIMT
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.88748x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 112.80 x 0.88748
€100.11
Value per share (EUR) From above. €100.11
Current discount Discount to share price of €17.94
= -1 x (€17.94 - €100.11) / €100.11
82.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Aimmune Therapeutics is available for.
Intrinsic value
>50%
Share price is €17.94 vs Future cash flow value of €100.11
Current Discount Checks
For Aimmune Therapeutics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Aimmune Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Aimmune Therapeutics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Aimmune Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Aimmune Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:5TA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-3.67
NasdaqGS:AIMT Share Price ** NasdaqGS (2019-04-18) in USD $20.21
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Aimmune Therapeutics.

DB:5TA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:AIMT Share Price ÷ EPS (both in USD)

= 20.21 ÷ -3.67

-5.5x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Aimmune Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Aimmune Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Aimmune Therapeutics's expected growth come at a high price?
Raw Data
DB:5TA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -5.5x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 11 Analysts
59%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Aimmune Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Aimmune Therapeutics's assets?
Raw Data
DB:5TA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $4.81
NasdaqGS:AIMT Share Price * NasdaqGS (2019-04-18) in USD $20.21
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.85x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:5TA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:AIMT Share Price ÷ Book Value per Share (both in USD)

= 20.21 ÷ 4.81

4.2x

* Primary Listing of Aimmune Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Aimmune Therapeutics is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Aimmune Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Aimmune Therapeutics has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

5TA Future Performance

 How is Aimmune Therapeutics expected to perform in the next 1 to 3 years based on estimates from 11 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
59%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Aimmune Therapeutics expected to grow at an attractive rate?
  • Aimmune Therapeutics's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Aimmune Therapeutics's earnings growth is expected to exceed the Germany market average.
  • Unable to compare Aimmune Therapeutics's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:5TA Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:5TA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 11 Analysts 59%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.4%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:5TA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 11 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:5TA Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 1,089 154 558 5
2022-12-31 631 40 218 5
2021-12-31 266 -72 -34 6
2020-12-31 73 -239 -195 10
2019-12-31 0 -230 -247 11
DB:5TA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -169 -211
2018-09-30 -150 -195
2018-06-30 -133 -175
2018-03-31 -116 -155
2017-12-31 -100 -131
2017-09-30 -90 -115
2017-06-30 -77 -106
2017-03-31 -68 -91
2016-12-31 -57 -81
2016-09-30 -53 -72
2016-06-30 -50 -59
2016-03-31 -43 -48

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Aimmune Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Aimmune Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:5TA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 11 Analyst Estimates (S&P Global) See Below

All data from Aimmune Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:5TA Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 4.92 5.66 4.18 2.00
2022-12-31 3.17 4.54 1.50 4.00
2021-12-31 -0.90 -0.25 -2.14 4.00
2020-12-31 -3.08 -2.30 -4.44 8.00
2019-12-31 -4.04 -3.66 -4.72 10.00
DB:5TA Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -3.67
2018-09-30 -3.53
2018-06-30 -3.29
2018-03-31 -3.02
2017-12-31 -2.61
2017-09-30 -2.35
2017-06-30 -2.25
2017-03-31 -2.03
2016-12-31 -1.89
2016-09-30 -1.72
2016-06-30 -1.56
2016-03-31 -1.69

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Aimmune Therapeutics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Aimmune Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Aimmune Therapeutics has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

5TA Past Performance

  How has Aimmune Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Aimmune Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Aimmune Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Aimmune Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Aimmune Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Aimmune Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Aimmune Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:5TA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -210.75 81.92 133.42
2018-09-30 -194.92 69.50 129.05
2018-06-30 -175.01 59.44 118.42
2018-03-31 -154.96 51.70 105.35
2017-12-31 -131.33 43.95 89.33
2017-09-30 -115.24 39.31 77.63
2017-06-30 -105.53 34.43 72.45
2017-03-31 -91.17 30.09 62.08
2016-12-31 -80.82 26.89 54.64
2016-09-30 -71.76 23.93 48.45
2016-06-30 -58.66 22.75 36.41
2016-03-31 -47.90 20.53 27.72
2015-12-31 -35.82 16.18 19.82
2015-09-30 -23.44 11.76 11.72
2015-06-30 -17.58 7.30 10.29
2015-03-31 -12.97 4.05 8.93
2014-12-31 -11.12 2.95 8.18
2013-12-31 -4.83 1.32 3.44

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Aimmune Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Aimmune Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Aimmune Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Aimmune Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Aimmune Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

5TA Health

 How is Aimmune Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Aimmune Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Aimmune Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Aimmune Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Aimmune Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 4007.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Aimmune Therapeutics Company Filings, last reported 3 months ago.

DB:5TA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 298.95 0.08 303.93
2018-09-30 247.16 0.00 255.25
2018-06-30 287.84 0.00 290.00
2018-03-31 329.09 0.00 321.88
2017-12-31 177.81 0.00 182.43
2017-09-30 210.59 0.00 212.03
2017-06-30 236.79 0.00 237.33
2017-03-31 264.72 0.00 246.25
2016-12-31 285.97 0.00 248.93
2016-09-30 160.50 0.00 150.24
2016-06-30 178.53 0.00 168.97
2016-03-31 193.40 0.00 180.28
2015-12-31 206.25 0.00 191.84
2015-09-30 218.89 0.00 216.61
2015-06-30 57.96 0.00 58.50
2015-03-31 64.24 0.00 65.31
2014-12-31 0.67 0.00 2.27
2013-12-31 11.64 0.00 11.95
  • Aimmune Therapeutics's level of debt (0%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (0% vs 0% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Aimmune Therapeutics has sufficient cash runway for 1.7 years based on current free cash flow.
  • Aimmune Therapeutics has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 47.8% each year.
X
Financial health checks
We assess Aimmune Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Aimmune Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

5TA Dividends

 What is Aimmune Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Aimmune Therapeutics dividends. Estimated to be 0% next year.
If you bought €2,000 of Aimmune Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Aimmune Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Aimmune Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:5TA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 11 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:5TA Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 2.00
2020-12-31 0.00 3.00
2019-12-31 0.00 3.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Aimmune Therapeutics has not reported any payouts.
  • Unable to verify if Aimmune Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Aimmune Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Aimmune Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Aimmune Therapeutics's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Aimmune Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Aimmune Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Aimmune Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

5TA Management

 What is the CEO of Aimmune Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jayson Donald Dallas
AGE 50
TENURE AS CEO 0.8 years
CEO Bio

Dr. Jayson Donald Alexander Dallas, M.D. has been President, Chief Executive Officer and Director of Aimmune Therapeutics, Inc. since June 19, 2018. He served as the Chief Commercial Officer and Executive Vice President at Ultragenyx Pharmaceutical Inc. since August 3, 2015 until June 18, 2018 and from January 2016 to June 18, 2018 respectively. Dr. Dallas commenced employment with Ultragenyx in August 2015. He served as Senior Vice President at Ultragenyx since August 3, 2015 until January 2016. He served as General Manager of Roche in the United Kingdom from July 2012 to July 2015. Prior to this, at Genentech, he held two different positions as Head of Global Oncology Launch Excellence and Biosimilar Strategy and Head of Global Product Strategy for Immunology and Ophthalmology from May 2010 to June 2012. Prior to Genentech, he worked at Novartis and Pharmacia in the US and previously at Roche in Switzerland. Over the course of his 21 year career in the industry, he has successfully overseen multiple product launches, internationally and in the US and has led numerous commercial organizations through periods of rapid growth. He worked in various medical functions within the industry and also as a practicing clinician. He has been an Independent Director of Arena Pharmaceuticals, Inc. since February 14, 2017. Dr. Dallas holds an MD from the University of the Witwatersrand, Johannesburg, South Africa and an MBA from Ashridge Business School in the United Kingdom.

CEO Compensation
  • Insufficient data for Jayson Donald to compare compensation growth.
  • Insufficient data for Jayson Donald to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Aimmune Therapeutics management team in years:

3
Average Tenure
52
Average Age
  • The tenure for the Aimmune Therapeutics management team is about average.
Management Team

Eric Bjerkholt

TITLE
Chief Financial Officer
COMPENSATION
$4M
AGE
58
TENURE
2 yrs

Jeff Knapp

TITLE
Chief Operating Officer
COMPENSATION
$2M
AGE
52
TENURE
3.2 yrs

Doug Sheehy

TITLE
General Counsel & Secretary
COMPENSATION
$2M
AGE
51
TENURE
3 yrs

Stephen Dilly

TITLE
Special Advisor
COMPENSATION
$7M
AGE
58
TENURE
0.8 yrs

Dan Adelman

TITLE
Chief Medical Officer
COMPENSATION
$2M
AGE
61
TENURE
2.8 yrs

Jayson Donald Dallas

TITLE
President
AGE
50
TENURE
0.8 yrs

Laura Hansen

TITLE
Vice President of Investor Relations
TENURE
3.1 yrs

Alison Marquiss

TITLE
Vice President of Community and Public Affairs

Mary Rozenman

TITLE
Senior Vice President of Corporate & Strategy Development
COMPENSATION
$1M
AGE
37
TENURE
3.2 yrs

William Turner

TITLE
Senior Vice President of Global Regulatory Affairs & Quality Assurance
TENURE
3.2 yrs
Board of Directors Tenure

Average tenure and age of the Aimmune Therapeutics board of directors in years:

3.1
Average Tenure
54.5
Average Age
  • The tenure for the Aimmune Therapeutics board of directors is about average.
Board of Directors

Mark McDade

TITLE
Chairman
COMPENSATION
$281K
AGE
63
TENURE
3.9 yrs

Jayson Donald Dallas

TITLE
President
AGE
50
TENURE
0.8 yrs

Patrick Enright

TITLE
Director
COMPENSATION
$253K
AGE
57
TENURE
6 yrs

Kate Falberg

TITLE
Director
COMPENSATION
$263K
AGE
57
TENURE
3.9 yrs

Stacey Seltzer

TITLE
Director
COMPENSATION
$251K
AGE
41
TENURE
4.3 yrs

Mark Iwicki

TITLE
Director
COMPENSATION
$247K
AGE
52
TENURE
3.9 yrs

Kirsten Beyer

TITLE
Member of Scientific Advisory Board
TENURE
2.3 yrs

A. Burks

TITLE
Member of Scientific Advisory Board
TENURE
2.3 yrs

Thomas Casale

TITLE
Member of Scientific Advisory Board
TENURE
2.3 yrs

Jonathan Hourihane

TITLE
Member of Scientific Advisory Board
TENURE
2.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
20. Nov 18 Buy Jayson Donald Dallas Individual 19. Nov 18 19. Nov 18 3,650 €24.06 €87,822
14. Jun 18 Buy Eric Bjerkholt Individual 13. Jun 18 13. Jun 18 1,600 €25.83 €41,325
X
Management checks
We assess Aimmune Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Aimmune Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

5TA News

Simply Wall St News

5TA Company Info

Description

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow’s milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.

Details
Name: Aimmune Therapeutics, Inc.
5TA
Exchange: DB
Founded: 2011
$1,123,130,971
62,469,685
Website: http://www.aimmune.com
Address: Aimmune Therapeutics, Inc.
8000 Marina Boulevard,
Suite 300,
Brisbane,
California, 94005,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS AIMT Common Stock Nasdaq Global Select US USD 06. Aug 2015
DB 5TA Common Stock Deutsche Boerse AG DE EUR 06. Aug 2015
LSE 0HBB Common Stock London Stock Exchange GB USD 06. Aug 2015
Number of employees
Current staff
Staff numbers
215
Aimmune Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 22:20
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/17
Last earnings filing: 2019/02/28
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.